Overview
This actively managed, diversified equity fund invests in Swiss equities that offer a high dividend yield
The fund aims to generate additional income by selling call options on the stocks held in the fund. With this the fund aims to provide some downside cushion during market corrections and in return is expected to give up some upside during strongly rising equity markets
The fund focuses on quality factors to exclude low quality stocks, including the company’s ability to pay stable or growing dividends
The strategy is based on fundamental research
The fund intends to distribute capital (premiums from writing call options) as well as income (e.g. from dividends). See risk section below.
Benefits
Easy access to a high quality equity portfolio which aims to provide some downside cushion during market corrections
Strong income component generated from dividends and call option premiums
Investors can profit from a portfolio that seeks optimal diversification on both sector and single stock level
Risks
Features
| Product category |
Equity Switzerland |
| Product domicile |
Switzerland
|
| Portfolio management |
UBS SA国际传谋 Switzerland AG, Zurich
|
| Fund management |
UBS Fund Management (Switzerland) AG
|
| Custodian bank |
UBS Switzerland AG, Zurich
|
| Day of inception |
December 6, 2021
|
| Currency of account |
CHF
|
| Close of financial year |
October 31
|
| SFDR Classification |
n.a.
|
| Issue / redemption |
daily
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
0.00% p.a.
|
| Flat fee |
0.00% p.a.
|
| Management fee |
0.00% p.a.
|
| Total expense ratio (TER) |
0.00% p.a.
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
SPI® (TR)
|
| Cut-Off Time |
15:00h(CET)
|
| Securities no. |
113999542
|
| ISIN |
CH1139995422
|
| Bloomberg Ticker |
UBSICIX SW
|
| Telekurs Id |
EFSWIX
|
Performance and Prices
Percentage growth
as of April 23, 2026| CHF(%) | EUR(%) | USD(%) | |
| YTD | 1.72 | 3.09 | 2.67 |
| 1M | |||
| 3M | |||
| 6M | |||
| 1Y | |||
| 2Y | 13.97 | 15.34 | 30.65 |
| 3Y | |||
| 5Y | |||
| ø p.a.5Y | 6.25 | 9.42 | 11.72 |
Current data
| Net asset value | 23.04.2026 | CHF 93.43 |
| High - last 12 months | 06.01.2026 | CHF 99.90 |
| Low - last 12 months | 20.03.2026 | CHF 86.24 |
| Last distribution | 16.01.2026 | CHF 7.49 |
| Assets of the unit class in mn | 23.04.2026 | CHF 99.31 |
| Total product assets in mn | 23.04.2026 | CHF 2,959.08 |
| Indicative current equity yield | 31.03.2026 | 8.24% |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 11.72% | 12.29% |
| Sharpe Ratio | 31.03.2026 | 0.72 | n.a. |
| Risk Free Rate | 31.03.2026 | 0.46% | 0.40% |
Structures
By the 10 largest equity positions (in %, as of March 31, 2026)
|
|
|
| Nestle SA | 9.89 |
| Novartis AG | 9.75 |
| Roche Holding AG | 9.07 |
| Zurich Insurance Group AG | 8.81 |
| UBS Group AG | 8.34 |
| ABB Ltd | 8.27 |
| Swiss Re AG | 5.52 |
| Cie Financiere Richemont SA | 4.36 |
| Givaudan SA | 4.00 |
| Lonza Group AG | 3.81 |
Fees
Distributions
|
Date of distribution
|
Pay date
|
Cps no.
|
Currency
|
Tax domicile CH gross amount
|
Tax domicile CH net amount
|
Tax domicile not CH gross amount
|
Tax domicile not CH net amount
|
Remarks
|
|||||||||||
| 14.01.2026 | 16.01.2026 | 7 | CHF | 2.66 | 1.73 | 2.66 | 1.73 | Income | 14.01.2026 | 16.01.2026 | 8 | CHF | 4.83 | 4.83 | 4.83 | 4.83 | Capital gain or income from direct property |
Sales Authorisations
Literature
|
Document type
|
Document Language
|
|||
| Prospectus |
|
|
||
| Key Information Document |
|
|
|
|
| Past performance |
|
|
|
|
| Previous performance scenario |
|
|
|
|
|
Document type
|
Document Language
|
|
| Annual report |
|
|
| Semi-annual report |
|
|